Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Urine Sediment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43895   clinical trials with a EudraCT protocol, of which   7301   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: Urine Sediment. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2011-005856-32 Sponsor Protocol Number: RITULUP Start Date*: 2012-05-21
    Sponsor Name:Fundación Progreso y Salud
    Full Title: Comparison of the efficacy of two rituximab treatment regimens in patients with lupus nephropathy resistant to conventional treatment
    Medical condition: Long-term relapse after treatment of lupus nephritis (LN) resistant to conventional treatment
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-002159-32 Sponsor Protocol Number: 211LE201 Start Date*: 2012-03-30
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) BE (Completed) DE (Completed) ES (Prematurely Ended) HU (Completed) IT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005979-16 Sponsor Protocol Number: PrOvAS001 Start Date*: 2013-04-29
    Sponsor Name:Instituto de Investigación Sanitaria La Fe
    Full Title: PREECLAMPSIA OF PREVENTION IN PATIENTS THROUGH ovodonation aspirin in early gestation
    Medical condition: PREECLAMPSIA
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003372-73 Sponsor Protocol Number: ZTI-01-200 Start Date*: 2016-04-11
    Sponsor Name:Zavante Therapeutics, Inc.
    Full Title: A Multi-center, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 Versus Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, In...
    Medical condition: Complicated Urinary Tract Infections, Including Acute Pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10037597 Pyelonephritis acute PT
    19.0 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) LT (Completed) LV (Completed) SK (Completed) PL (Completed) EE (Completed) GR (Completed) BG (Completed) RO (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2007-004518-15 Sponsor Protocol Number: 28113 Start Date*: 2008-08-05
    Sponsor Name:Merck Serono International
    Full Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atacicept in Subjects with Lupus Nephritis in Combination with Mycophenolate Mofetil Therapy
    Medical condition: Lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025140 Lupus nephritis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002554-78 Sponsor Protocol Number: PB-102-F02 Start Date*: 2013-08-29
    Sponsor Name:Protalix Ltd.
    Full Title: An Extension of Phase 1/2, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion ...
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-003244-13 Sponsor Protocol Number: D4280C00016 Start Date*: 2015-04-17
    Sponsor Name:Pfizer Inc.
    Full Title: A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam compared with cefepime in children fr...
    Medical condition: Complicated urinary tract infections
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000005053 10046577 Urinary tract infections HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) GR (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-001442-29 Sponsor Protocol Number: D3461C00007 Start Date*: 2016-01-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005609-28 Sponsor Protocol Number: RAV-IgA Start Date*: 2022-03-18
    Sponsor Name:Dr. Alfons Segarra Medrano
    Full Title: A PILOT PROOF-OF–CONCEPT STUDY TO ASSESS THE EFFICACY AND SAFETY OF A 6 MONTHS RAVULIZUMAB TREATMENT IN PATIENTS WITH FLARES OF CORTICOSTEROID-RESISTANT IDIOPATHIC IgA NEPHROPATHY
    Medical condition: Treatment for IgA nephropathy flares
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004786-40 Sponsor Protocol Number: PB-102-F01 Start Date*: 2013-05-10
    Sponsor Name:Protalix Ltd.
    Full Title: A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks ...
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-005357-29 Sponsor Protocol Number: WA20500 Start Date*: 2008-05-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Subjects With WHO or ISN Class III or IV Nephrit...
    Medical condition: Lupus Nephritis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) DE (Completed) HU (Completed) ES (Completed) NL (Completed) PT (Prematurely Ended) SE (Completed) PL (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-003211-57 Sponsor Protocol Number: CAIN457Q12301 Start Date*: 2020-03-26
    Sponsor Name:Novartis Pharma AG
    Full Title: A two-year, phase III randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo, in combination...
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) NO (Prematurely Ended) GB (GB - no longer in EU/EEA) PT (Prematurely Ended) DE (Completed) SE (Prematurely Ended) DK (Prematurely Ended) GR (Ongoing) LV (Prematurely Ended) ES (Prematurely Ended) HR (Completed) FR (Completed) IT (Prematurely Ended) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002608-29 Sponsor Protocol Number: CS2514-2017-0003 Start Date*: 2017-12-12
    Sponsor Name:Entasis Therapeutics
    Full Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infe...
    Medical condition: Complicated Urinary Tract Infection including Acute Pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10037597 Pyelonephritis acute PT
    20.0 100000005053 10046577 Urinary tract infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-015403-95 Sponsor Protocol Number: NS10364-3 Start Date*: 2010-02-11
    Sponsor Name:Faculty Hospital Hradec Králové
    Full Title: A pilot trial of noninvasive assessment of methotrexate hepatotoxicity in the course of pharmacokinetically guided pharmacotherapy of psoriasis with methotrexate and folic acid
    Medical condition: moderate-severe and severe plaque psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000714-11 Sponsor Protocol Number: IM101-291 Start Date*: 2013-04-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil (MMF) and Corticostero...
    Medical condition: Active Class III or IV lupus glomerulonephritis
    Disease: Version SOC Term Classification Code Term Level
    15.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) CZ (Completed) ES (Completed) RO (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-004917-41 Sponsor Protocol Number: WX17801 Start Date*: 2005-09-05
    Sponsor Name:Aspreva International Ltd.
    Full Title: A prospective, randomized, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in s...
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    4.1 10025140 Low
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) CZ (Completed) ES (Completed) BE (Completed) PT (Completed) AT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022096-54 Sponsor Protocol Number: Repha_1344 Start Date*: 2011-04-04
    Sponsor Name:Repha GmbH
    Full Title: Randomised, prospective, double-dummy double-blinded study to evaluate safety and efficacy of Angocin Anti-Infekt N versus standard antibiotics in the treatment of acute uncomplicated cystitis
    Medical condition: Treatment of acute uncomplicated cystitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10011781 Cystitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002221-36 Sponsor Protocol Number: 28779 Start Date*: 2008-10-17
    Sponsor Name:Merck Serono International, An affiliate of Merck KGaA, Darmstadt, Germany
    Full Title: A Phase II/III, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of atacicept in combination with corticosteroids and sequential therapy with cyclophosphamide ...
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025140 Lupus nephritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-005117-31 Sponsor Protocol Number: W-4282-301 Start Date*: 2018-10-17
    Sponsor Name:Wockhardt Bio AG
    Full Title: A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem followed by Optional Oral Therapy in the Treatment of...
    Medical condition: Complicated urinary tract infection or acute pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    20.1 10021881 - Infections and infestations 10037597 Pyelonephritis acute PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Temporarily Halted) BG (Temporarily Halted) LV (Temporarily Halted) LT (Temporarily Halted) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003671-35 Sponsor Protocol Number: SPR994-301 Start Date*: 2019-04-18
    Sponsor Name:Spero Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) ...
    Medical condition: complicated urinary tract infection or acute pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10046571 Urinary tract infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed) BG (Completed) HU (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 23:32:08 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA